CN106794986A - 氘化或非氘化分子以及药物制剂 - Google Patents

氘化或非氘化分子以及药物制剂 Download PDF

Info

Publication number
CN106794986A
CN106794986A CN201580055310.6A CN201580055310A CN106794986A CN 106794986 A CN106794986 A CN 106794986A CN 201580055310 A CN201580055310 A CN 201580055310A CN 106794986 A CN106794986 A CN 106794986A
Authority
CN
China
Prior art keywords
site
deuterated
tetrahydrocurcumin
pharmaceutical formulation
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580055310.6A
Other languages
English (en)
Chinese (zh)
Inventor
布平德尔·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubu Treatment Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN106794986A publication Critical patent/CN106794986A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/17—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/172—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580055310.6A 2014-09-02 2015-08-31 氘化或非氘化分子以及药物制剂 Pending CN106794986A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044566P 2014-09-02 2014-09-02
US62/044,566 2014-09-02
PCT/US2015/047822 WO2016036674A1 (en) 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CN106794986A true CN106794986A (zh) 2017-05-31

Family

ID=55401248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580055310.6A Pending CN106794986A (zh) 2014-09-02 2015-08-31 氘化或非氘化分子以及药物制剂

Country Status (9)

Country Link
US (3) US9375408B2 (https=)
EP (2) EP3628640B1 (https=)
JP (3) JP2017527614A (https=)
CN (1) CN106794986A (https=)
AU (4) AU2015312134A1 (https=)
CA (1) CA2959965A1 (https=)
IL (2) IL285760B2 (https=)
MX (2) MX372723B (https=)
WO (1) WO2016036674A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111017878A (zh) * 2019-12-18 2020-04-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
CN111759820A (zh) * 2020-08-24 2020-10-13 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
US10934241B2 (en) * 2017-06-16 2021-03-02 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
US11117907B2 (en) 2017-06-16 2021-09-14 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
KR20210019459A (ko) * 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020181256A1 (en) * 2019-03-06 2020-09-10 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3142023A1 (en) * 2019-05-28 2020-12-03 Case Western Reserve University Compositions and methods for preserving dna methylation
JP7422473B2 (ja) * 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
WO2021138561A1 (en) * 2019-12-31 2021-07-08 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
US11883371B2 (en) * 2020-03-23 2024-01-30 Renibus Therapeutics, Inc. Stress test and treatment of chronic kidney disease
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
AU2021281223A1 (en) 2020-05-27 2023-01-05 Case Western Reserve University Compositions and methods for preserving DNA methylation
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途
CN102526003A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CZ301771B6 (cs) 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
US8841326B2 (en) * 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
CN1283237C (zh) 2004-11-22 2006-11-08 山东大学 姜黄素磷脂复合物及其制备方法
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
JP2007320864A (ja) * 2006-05-30 2007-12-13 Toshihiko Osawa 非アルコール性脂肪肝炎予防・治療用組成物
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
JP2008201768A (ja) * 2006-11-24 2008-09-04 Mizu Kk 抗炎症剤及びシクロオキシゲナーゼ阻害剤
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
WO2010097643A1 (en) * 2009-02-24 2010-09-02 Novatech Istrazivanje D.O.O. Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
JP5416472B2 (ja) * 2009-05-07 2014-02-12 株式会社セラバリューズ ウコン色素組成物による心機能改善効果
CN101627969B (zh) * 2009-07-30 2011-06-29 浙江工业大学 一种姜黄素自乳化给药系统及其制备
WO2011047309A2 (en) * 2009-10-16 2011-04-21 The Research Foundation Of State University Of New York Treatment of ischemic tissue
WO2011116066A1 (en) * 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2013033250A1 (en) * 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
CN104739813A (zh) * 2013-12-26 2015-07-01 四川省中医药科学院 四氢姜黄素的新用途
EP3628640B1 (en) * 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途
CN102526003A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEELAVINOTHAN PARI ET AL.: "Tetrahydrocurcumin: Effect on Chloroquine-Mediated Oxidative Damage in Rat Kidney", 《BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY》 *
PIDARAN MURUGAN ET AL.: "Antioxidant effect of tetrahydrocurcumin in streptozotocin–nicotinamide induced diabetic rats", 《LIFE SCIENCES》 *
刘必成: "《慢性肾脏病新理论与实践》", 31 January 2008, 东南大学出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111017878A (zh) * 2019-12-18 2020-04-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
CN111017878B (zh) * 2019-12-18 2021-12-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
CN111759820A (zh) * 2020-08-24 2020-10-13 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
CN111759820B (zh) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法

Also Published As

Publication number Publication date
AU2019250097A1 (en) 2019-10-31
IL285760A (en) 2021-09-30
MX2020005446A (es) 2020-08-27
EP3189007B1 (en) 2019-10-02
JP2021001193A (ja) 2021-01-07
MX372723B (es) 2020-06-19
AU2023274063A1 (en) 2023-12-14
JP2017527614A (ja) 2017-09-21
WO2016036674A1 (en) 2016-03-10
IL250861A0 (en) 2017-04-30
US20200377441A1 (en) 2020-12-03
EP3628640A1 (en) 2020-04-01
IL285760B2 (en) 2025-03-01
US9375408B2 (en) 2016-06-28
CA2959965A1 (en) 2016-03-10
EP3189007A4 (en) 2018-05-16
US20160058713A1 (en) 2016-03-03
AU2015312134A1 (en) 2017-03-23
IL285760B1 (en) 2024-11-01
US10781158B2 (en) 2020-09-22
IL250861B (en) 2021-09-30
US20170029354A1 (en) 2017-02-02
EP3189007A1 (en) 2017-07-12
JP2023011921A (ja) 2023-01-24
EP3628640B1 (en) 2023-08-09
AU2021236495A1 (en) 2021-10-21
MX2017002750A (es) 2017-08-02

Similar Documents

Publication Publication Date Title
JP2023011921A (ja) 重水素化又は非重水素化分子及び医薬製剤
CN106604725B (zh) 治疗肥胖症，防止体重增加，促进体重减轻或治疗或预防糖尿病的发展的方法和组合物
CN106955297B (zh) 管花肉苁蓉萃取物及异类叶升麻苷于保护肌肉的用途
CN108653276B (zh) 一种3-芳基香豆素类化合物的应用
CN120435297A (zh) 一种用于防治糖尿病及其并发症的人参二醇皂苷组合物及其制备方法和应用
US20110300246A1 (en) Herbal Extracts for Treatment of Diabetic Complications and Oxidative Stress
CN102731597B (zh) 黄蜀葵花提取物及其化学成分的用途
US20200009169A1 (en) Compounds, compositions and methods for prevention or treatment of liver, lipid, and glucose-related conditions
HK40026907A (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
Wang et al. Anti-hyperglycemic effect of the polysaccharide fraction isolated from Mactra veneriformis
HK40026907B (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
KR102279105B1 (ko) 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물
CN109620857B (zh) 花生衣活性组分及其在制备抗肥胖抗糖尿病药物中的应用
KR20100060949A (ko) 신경세포 보호용 조성물
CN106563038B (zh) 一种牛磺酸和脂溶性茶多酚复方组合物及其制备方法与应用
CN115581702A (zh) 芍药素-3-o-阿拉伯糖苷在制备药物或保健食品的应用
HK40059232A (en) Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes
JP2024529643A (ja) スルフォラファンとグリシンとを含む混合物及び組成物
CN116726034A (zh) 化合物作为sirt1激动剂及用于制备改善代谢相关脂肪性肝病的药物中的应用
CN115645430A (zh) 飞燕草素-3-o-半乳糖苷在制备药物或保健食品的应用
KR20130043001A (ko) 브란디오사이드 또는 페리포사이드를 포함하는 당뇨합병증의 치료 또는 예방용 또는 항노화용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230626

Address after: Arizona

Applicant after: Hubu Treatment Co.

Address before: Arizona

Applicant before: Bupindele Singh

TA01 Transfer of patent application right